Bio

Clinical Focus


  • Laser Cataract Surgery
  • Femtosecond Laser
  • Cataract
  • Ophthalmology
  • Cataract Surgery

Academic Appointments


Administrative Appointments


  • Director, Byers Eye Surgery Center at Stanford (2012 - Present)
  • Clinic Chief, Department of Ophthalmology (2007 - Present)
  • Director, Cataract Surgery Service (2010 - Present)
  • Ophthalmology Delegate, Stanford OR Committee (2008 - Present)

Professional Education


  • Internship:St Mary's Medical Center (2002) CA
  • Medical Education:Yale University School of Medicine (2001) CT
  • Board Certification: Ophthalmology, American Board of Ophthalmology (2006)
  • Residency:Stanford University Medical Center (2005) CA
  • MD, Yale University (2001)
  • PhD, Yale University, Neuroscience (1999)
  • BA, Amherst College, Neuroscience (1991)

Community and International Work


  • Thimphu Hospital, Bhutan

    Topic

    International Ophthalmology Instruction

    Partnering Organization(s)

    Health Volunteers Overseas

    Populations Served

    Bhutan

    Location

    International

    Ongoing Project

    No

    Opportunities for Student Involvement

    No

  • Arbor Clinic

    Topic

    Ophthalmology

    Populations Served

    under-served

    Location

    Bay Area

    Ongoing Project

    Yes

    Opportunities for Student Involvement

    No

Research & Scholarship

Current Research and Scholarly Interests


Multicenter Catalys Consortium Trial - To compare femtosecond laser assisted cataract surgery with conventional cataract surgery

Publications

Journal Articles


  • Comparison of One-Day Versus One-Hour Application of Topical Gatifloxacin in Eliminating Conjunctival Bacterial Flora OPHTHALMOLOGY Moss, J. M., Nguyen, D., Liu, Y. I., Singh, K., Montague, A., Egbert, P. R., de Kaspar, H. M., Ta, C. N. 2008; 115 (11): 2013-2016

    Abstract

    To compare efficacies of 1-day, 1-hour, and combined 1-day/1-hour preoperative topical gatifloxacin in eliminating conjunctival bacterial flora.Prospective, comparative case series.Sixty patients (120 eyes) scheduled to undergo anterior segment intraocular surgery at Stanford University Medical Center.Cultures were collected from the palpebral conjunctival sac at baseline and after 1 day (4 doses), 1 hour (3 doses), and 1 day/1 hour (7 doses) of gatifloxacin use.Incidence of positive bacterial samples collected pre- and post-antibiotic treatment and number of colony forming units (CFUs).SeptiChek (Becton Dickinson, Franklin Lakes, NJ) positive cultures significantly decreased from 67% growth at baseline to 28% (P<0.0001) after 1 day and from 60% at baseline to 37% (P = 0.018) after 1 hour of gatifloxacin use. Reductions of 44% growth at baseline to 12% (P = 0.0001) after 1 day and 32% at baseline to 13% (P = 0.029) after 1 hour of gatifloxacin use were observed on blood agar. Surgical eyes that received both 1-day and 1-hour preoperative gatifloxacin had reductions from 67% growth at baseline to 18% posttreatment (P<0.0001) and 45% at baseline to 7% posttreatment (P<0.0001) on SeptiChek and blood agar media, respectively. In addition to a lower frequency of positive cultures, a significantly lower CFU count was found after 1-day (P = 0.004) and 1-hour (P = 0.049) gatifloxacin use compared with pretreatment levels. Combined 1-day/1-hour doses of gatifloxacin were associated with a greater reduction in CFUs (P = 0.001) when compared with 1-hour treatment alone.Both 1-hour and 1-day topical gatifloxacin use are effective in reducing the frequency of conjunctival bacterial growth and the overall bacterial load as measured by CFUs, relative to baseline. Although a 1-hour pretreatment is associated with a reduction in bacterial growth, the combination of 1-day and 1-hour preoperative gatifloxacin dosing results in an even lower overall bacterial load, suggesting that the latter might be the preferred preoperative regimen for eyes undergoing anterior segment surgery.

    View details for DOI 10.1016/j.ophtha.2008.06.024

    View details for Web of Science ID 000260448900024

    View details for PubMedID 18708260

  • Prospective comparison of topical moxifloxacin in eliminating conjunctival bacterial flora following a one-day or one-hour application JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS Ta, C. N., Chan, I., Dhatt, H. S., Paterno, J., Fisher, E., Singh, K., Montague, A., Egbert, P. R., Cockerham, G., de Kaspar, H. M. 2008; 24 (4): 427-431

    Abstract

    The aim of this study was to compare the efficacy of a 1-hour(h) versus 1-day application of topical moxifloxacin in eliminating conjunctival bacterial flora.In this prospective, nonrandomized, controlled trial, the surgical eyes of 60 patients scheduled for intraocular surgery received topical moxifloxacin four times a day, starting 1 day prior to surgery and three additional applications at 5-minute intervals 1 h before surgery. The nonsurgical eye of each patient only received three applications of the same antibiotic at 5-minute intervals 1 h before surgery. Conjunctival cultures were obtained at baseline and after antibiotic application.Prior to antibiotic application, 80% of surgical eyes and 70% of nonsurgical eyes had positive cultures. Following the 1-day application, significantly fewer eyes (40%) had positive cultures (P < 0.0001), with a further reduction to 32% with three additional doses 1 h prior to surgery. In the nonsurgical eye, the decrease in the percentage of positive cultures, from 55% to 53% following the three applications 1 h prior to surgery, was not significant (P > 0.9999). The 1-day application was associated with significantly fewer positive cultures, compared to the 1-h group (P = 0.0267).The one-day application of moxifloxacin resulted in significantly fewer positive conjunctival cultures, compared with a 1-h application.

    View details for DOI 10.1089/jop.2008.0018

    View details for Web of Science ID 000258731100011

    View details for PubMedID 18665815

  • CustomVue laser in situ keratomileusis treatment after previous keratorefractive surgery JOURNAL OF CATARACT AND REFRACTIVE SURGERY Montague, A. A., Manche, E. E. 2006; 32 (5): 795-798

    Abstract

    To evaluate the efficacy, predictability, and safety of Visx CustomVue wavefront-guided enhancement after previous keratorefractive surgery.Stanford University Eye Laser Center, Stanford, California, USA.A retrospective analysis was used to evaluate wavefront-guided enhancement in a preliminary set of 120 eyes of 102 patients. All eyes had previous keratorefractive surgery (photorefractive keratoplasty [PRK] in 1 eye, laser in situ keratomileusis [LASIK] in 119 eyes); the prekeratorefractive surgery spherical equivalent (SE) refraction ranged from -1.25 diopters (D) to -7.00 D. Primary outcome variables including uncorrected visual acuity (UCVA), manifest refraction, and complications were evaluated at 1 and 3 months.At 1 month, the mean pre-enhancement SE was reduced from -0.91 D +/- 0.40 (SD) (range -2.375 to -0.125 D) to -0.13 +/- 0.33 D (range -1.25 to 0.75 D) with 91% of eyes within +/-0.5 D of emmetropia and 100% within +/-1.0 D. All eyes showed equal or improved UCVA (range 20/15 to 20/30) with 20/20 or better in 84 of 91 eyes. At 3 months, the mean was -0.20 +/- 0.32 D (range -0.75 to 0.75 D) with 100% of eyes within +/-0.75 D of emmetropia. All eyes showed equal or improved UCVA (range 20/15 to 20/30) with 20/20 or better in 74 of 84 eyes. Higher-order wavefront aberration analysis showed that the mean root-mean-square error was reduced from 0.39 +/- 0.14 microm (range 0.16 to 0.86 microm) to 0.34 +/- 0.12 microm (range 0.12 to 0.78 microm). Coma was reduced from 0.22 +/- 0.13 microm (range 0.02 to 0.71 microm) to 0.16 +/- 0.11 microm (range 0.01 to 0.62 microm), and trefoil was reduced from 0.16 +/- 0.09 microm (range 0.01 to 0.62 microm) to 0.11 +/- 0.07 microm (range 0.01 to 0.27 microm). Spherical aberration was unchanged from 0.14 +/- 0.14 microm (range -0.18 to 0.59 microm) to 0.14 +/- 0.14 microm (range -0.16 to 0.5 microm).Preliminary data show that Visx CustomVue wavefront-guided enhancement after keratorefractive surgery is an effective, predictable, and safe procedure.

    View details for DOI 10.1016/j.jcrs.2006.01.081

    View details for Web of Science ID 000238413000027

    View details for PubMedID 16765797

  • Differential distribution of ionotropic glutamate receptor subunits in the rat olfactory bulb JOURNAL OF COMPARATIVE NEUROLOGY Montague, A. A., Greer, C. A. 1999; 405 (2): 233-246

    Abstract

    The subcellular localization of ionotropic glutamate receptor (GluR) subunits was examined with light and electron microscopy in the rat olfactory bulb by using antibodies to alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptor subunits: GluR1, GluR2/3, and GluR4; and kainate (KA) receptor subunits: GluR5/6/7. Immunoreactivity to GluR1 was heavy in the glomerular layer, moderate in the external plexiform layer, and localized to periglomerular somata and dendrites, short axon somata and dendrites, mitral cell somata, and mitral/tufted dendrites. GluR2/3 immunoreactivity was heavy in the external plexiform and glomerular layers and localized to periglomerular somata and dendrites, mitral cell somata, mitral/tufted dendrites, granule cell somata, and olfactory nerve-associated glia. GluR4 immunoreactivity showed heavy staining in the external plexiform and olfactory nerve layers with localization to mitral cells, mitral/tufted dendritic processes, and olfactory nerve glial processes. GluR5/6/7 immunoreactivity was heavy in the external plexiform layer, moderate in the olfactory nerve and glomerular layers, and localized to granule cells, mitral cells, and mitral/tufted dendritic processes. Ultrastructural immunolabeling for all antibodies examined showed immunoreactivity in the postsynaptic membrane and densities, adjacent dendritic cytoplasm, and somatic cytoplasm. These data demonstrate a highly specific laminar, cellular, and subcellular distribution of ionotropic GluR subunits within the primary afferent and local synaptic circuits of the olfactory bulb. The results are consistent with the notion that the different roles subserved by glutamate in the olfactory bulb are actuated, in part, by a differential distribution of GluR subunits.

    View details for Web of Science ID 000078411900007

    View details for PubMedID 10023812

Stanford Medicine Resources: